JCJulita Chlebowicz

Julita Chlebowicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julita Chlebowicz has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Elizabeth J. Goldsmith

    Department of Biophysics, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8816, United States

    2 shared publications
  • Jacqueline Burré

    Brain and Mind Research Institute, Appel Alzheimer’s Disease Research Institute, Weill Cornell Medicine, New York, USA

    2 shared publications
  • André Pineda

    Brain and Mind Research Institute, Appel Alzheimer’s Disease Research Institute, Weill Cornell Medicine, New York, USA

    1 shared publication
  • Anthony R. Vega

    Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA

    1 shared publication
  • Ashari Kannangara

    Department of Biophysics, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8816, United States

    1 shared publication
  • Ashari R Kannangara

    Department of Biophysics, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    1 shared publication

Latest Publications

  • Open Access

    New insights into synaptic vesicle dysfunction in Parkinson's disease

    by Julita Chlebowicz, Violetta Ivanova, Jacqueline Burré

    Parkinson's disease (PD) is characterized by progressive motor and non-motor dysfunction arising from synaptic pathology that precedes neuronal loss. Synaptic dysfunction represents a central pathological mechanism in both familial and sporadic PD, with multiple PD-linked genes directly regulating synaptic vesicle (SV) trafficking. Here, we review recent studies linking SV dysfunction to PD pathology by examining how disease-linked proteins dysregulate distinct steps in the SV cycle and by exploring their cascading effects on synaptic physiology and circuit function. We highlight three critical pathogenic mechanisms: (1) impaired neurotransmitter import and storage, (2) disrupted SV pool organization, and (3) altered SV exocytosis and endocytosis. We also review recent studies investigating how presynaptic pathology triggers impairments in postsynaptic plasticity and circuit-level reorganization across brain regions. Together, these studies highlight that presynaptic SV dysfunction is a central mechanism in PD pathogenesis and therefore a promising target for developing therapeutic strategies aimed at reverting these early disease-driving synaptic changes. Plain language title: New insights into synaptic vesicle dysfunction in Parkinson's disease


  • Open Access

    Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy

    by Virginia Gao, Julita Chlebowicz, Karlton Gaskin, Juan A. Briano, Lauren E. Komer, André Pineda, Shrey Jhalani, Saad Ahmad, Eseosa Uwaifo, Luca S. Black, et al.

    Neurotransmitter release occurs through exocytosis of synaptic vesicles. α-Synuclein’s function and dysfunction in Parkinson’s disease and other synucleinopathies is thought to be tightly linked to synaptic vesicle binding. Age is the biggest risk factor for synucleinopathy, and ~15% of synaptic vesicle proteins have been linked to central nervous system diseases. Yet, age- and disease-induced changes in synaptic vesicles remain unexplored. Via systematic analysis of synaptic vesicles at the ultrastructural, protein, and lipid levels, we reveal specific changes in synaptic vesicle populations, proteins, and lipids over age in wild-type mice and in α-synuclein knockout mice with and without expression of human α-synuclein. Strikingly, we find several previously undescribed synaptic changes in mice lacking α-synuclein, suggesting that loss of α-synuclein function contributes to synaptic dysfunction. These findings not only provide insights into synaptic vesicle biology and disease mechanisms in synucleinopathy, but also serve as a baseline for further mechanistic exploration of age- and disease-related alterations in synaptic vesicles.


  • Open Access

    Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation

    by Julita Chlebowicz, William Russ, Dailu Chen, Anthony Vega, Steven Vernino, Charles L. White, Josep Rizo, Lukasz A. Joachimiak, Marc I. Diamond

    α-Synuclein (aSyn) aggregation underlies neurodegenerative synucleinopathies. aSyn seeds are proposed to replicate and propagate neuronal pathology like prions. Seeding of aSyn can be recapitulated in cellular systems of aSyn aggregation; however, the mechanism of aSyn seeding and its regulation are not well understood. We developed an mEos-based aSyn seeding assay and performed saturation mutagenesis to identify with single-residue resolution positive and negative regulators of aSyn aggregation. We not only found the core regions that govern aSyn aggregation but also identified mutants outside of the core that enhance aggregation. We identified local structure within the N terminus of aSyn that hinders the fibrillization propensity of its aggregation-prone core. Based on the screen, we designed a minimal aSyn fragment that shows a ~4-fold enhancement in seeding activity and enabled discrimination of synucleinopathies. Our study expands the basic knowledge of aSyn aggregation and advances the design of cellular systems of aSyn aggregation to diagnose synucleinopathies based on protein conformation.


  • Open Access

    Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening

    by Julita Chlebowicz, Radha Akella, John M Humphreys, Haixia He, Ashari R Kannangara, Shuguang Wei, Bruce Posner, Elizabeth J Goldsmith

    Introduction: WNK [with no lysine (K)] kinases are serine/threonine kinases associated with familial hyperkalemic hypertension (FHHt). WNKs are therapeutic targets for blood pressure regulation, stroke and several cancers including triple negative breast cancer and glioblastoma. Here, we searched for and characterized novel WNK kinase inhibitors. Methods: We used a ~210,000-compound library in a high-throughput screen, re-acquisition and assay, commercial specificity screens and crystallography to identify WNK-isoform-selective inhibitors. Results: We identified five classes of compounds that inhibit the kinase activity of WNK1: quinoline compounds, halo-sulfones, cyclopropane-containing thiazoles, piperazine-containing compounds, and nitrophenol-derived compounds. The compounds are strongly pan-WNK selective, inhibiting all four WNK isoforms. A class of quinoline compounds was identified that further shows selectivity among the WNK isoforms, being more potent toward WNK3 than WNK1. The crystal structure of the quinoline-derived SW120619 bound to the kinase domain of WNK3 reveals active site binding, and comparison to the WNK1 structure reveals the potential origin of isoform specificity. Discussion: The newly discovered classes of compounds may be starting points for generating pharmacological tools and potential drugs treating hypertension and cancer. Graphical Abstract:


  • Synthesis and Structural Characterization of Novel Trihalo-sulfone Inhibitors of WNK1

    by Melanie Rodriguez, Ashari Kannangara, Julita Chlebowicz, Radha Akella, Haixia He, Uttam K. Tambar, Elizabeth J. Goldsmith

    With No lysine (K) [WNK] kinases are structurally unique serine/threonine protein kinases that have therapeutic potential for blood pressure regulation and cancer. A novel class of trihalo-sulfone compounds was identified by high-throughput screening. Trihalo-sulfone 1 emerged as an effective inhibitor of WNK1 with an IC50 value of 1.6 mu M. Herein, we define chemical features necessary for inhibition of WNK1 using chemical synthesis and X-ray crystallography. Analogues that probed the role of specific functional groups to the inhibitory activity were synthesized. X-ray structures of trihalo-sulfone 1 and a second trihalo-sulfone 23 bound to WNK1 revealed active site binding to two of the three previously defined canonical inhibitor binding pockets as well as a novel binding site for the trihalo-sulfone moiety. The elucidation of these novel interaction sites may allow for the strategic design of even more selective and potent WNK inhibitors.